Cost-Effectiveness of Parallel Versus Sequential Testing of Genetic Aberrations for Stage IV Non-Small-Cell Lung Cancer in the Netherlands
PURPOSE: A large number of targeted treatment options for stage IV nonsquamous non-small-cell lung cancer with specific genetic aberrations in tumor DNA is available. It is therefore important to optimize diagnostic testing strategies, such that patients receive adequate personalized treatment that improves survival and quality of life. The aim of this study is to assess the efficacy (including diagnostic costs, turnaround time (TAT), unsuccessful tests, percentages of correct findings, therapeutic costs, and therapeutic effectiveness) of parallel next generation sequencing (NGS)-based versus... Mehr ...
Verfasser: |
Wolff, Henri B
Steeghs, Elisabeth M P
Mfumbilwa, Zakile A
Groen, Harry J M
Adang, Eddy M
Willems, Stefan M
Grünberg, Katrien
Schuuring, Ed
Ligtenberg, Marjolijn J L
Tops, Bastiaan B J
Coupé, Veerle M H |
Dokumenttyp: |
Artikel |
Erscheinungsdatum: |
2022 |
Reihe/Periodikum: |
Wolff , H B , Steeghs , E M P , Mfumbilwa , Z A , Groen , H J M , Adang , E M , Willems , S M , Grünberg , K , Schuuring , E , Ligtenberg , M J L , Tops , B B J & Coupé , V M H 2022 , ' Cost-Effectiveness of Parallel Versus Sequential Testing of Genetic Aberrations for Stage IV Non-Small-Cell Lung Cancer in the Netherlands ' , JCO Precision Oncology , vol. 6 , e2200201 . https://doi.org/10.1200/PO.22.00201 ; ISSN:2473-4284 |
Schlagwörter: |
Carcinoma
/ Non-Small-Cell Lung/diagnosis
/ Cost-Benefit Analysis
/ Humans
/ Lung Neoplasms/diagnosis
/ Netherlands/epidemiology
/ Quality of Life |
Sprache: |
Englisch |
Permalink: |
https://search.fid-benelux.de/Record/base-26825543 |
Datenquelle: |
BASE;
Originalkatalog |
Powered By: |
BASE |
Link(s) :
|
http://hdl.handle.net/11370/70907162-3621-478d-bc64-46f76a6f6b69 |